Causes of Non-Medication Hyperkalemia
In patients not taking potassium-affecting medications, hyperkalemia develops primarily from three mechanisms: reduced renal potassium excretion (most commonly from chronic kidney disease), increased potassium intake, or transcellular shifts of potassium from intracellular to extracellular space. 1
Primary Pathophysiologic Mechanisms
Hyperkalemia occurs when potassium homeostasis is disrupted through one or more of the following pathways 1:
1. Reduced Potassium Excretion
- Chronic kidney disease (CKD): The most common cause, occurring in up to 73% of patients with advanced CKD 1
- Acute kidney injury: Present in all cases of hyperkalemia-induced cardiac arrest in one retrospective study 2
- Diabetes mellitus with hyporeninemic hypoaldosteronism: A specific syndrome causing impaired aldosterone production 3
- Adrenal insufficiency: Primary or secondary adrenal disease reducing aldosterone secretion 4
The severity correlates directly with renal function—serum potassium levels are significantly related to creatinine and eGFR values (P<0.001), with creatinine ≥1.25 mg/dl and eGFR ≤60 ml/min/1.73 m² significantly associated with hyperkalemia severity 5.
2. Increased Potassium Intake
Even without supplements or medications, excessive dietary intake can cause hyperkalemia, particularly when combined with reduced renal excretion 1:
- High-potassium foods: Bananas, melons, orange juice
- Salt substitutes: Often contain potassium chloride (DASH diet products)
- Herbal supplements: Alfalfa, dandelion, noni juice, Siberian ginseng, hawthorne berry, horsetail, lily of the valley, milkweed, nettle
- Stored blood products: During transfusions
- Amino acids: Aminocaproic acid, arginine, lysine
3. Transcellular Potassium Shifts
Potassium movement from intracellular to extracellular space without total body potassium excess 1:
- Metabolic acidosis: Impairs Na+/K+ ATPase pump function
- Hyperglycemia: Causes osmotic shifts
- Tissue breakdown: Rhabdomyolysis, tumor lysis syndrome, hemolysis
- Acute pancreatitis: Identified in 3 of 7 cardiac arrest cases from hyperkalemia 2
- Acute hepatic failure: Identified in 2 of 7 cardiac arrest cases 2
High-Risk Clinical Conditions
Cardiovascular disease patients are at particularly high risk when combined with specific comorbidities 1:
- Heart failure: Hyperkalemia occurs in up to 40% of chronic HF patients 1
- Hypertension with CKD
- Coronary artery disease with diabetes
- Advanced age with multiple comorbidities
These conditions increase risk even without medications because they inherently impair potassium regulation through reduced renal function, altered aldosterone response, or both 1.
Critical Diagnostic Consideration: Pseudo-hyperkalemia
Before treating, always exclude pseudo-hyperkalemia—elevated potassium in the test tube without true body hyperkalemia 1. This occurs from:
- Potassium release during blood sampling (repeated fist clenching, poor phlebotomy technique)
- Hemolysis in the specimen
- Delayed specimen processing
- Thrombocytosis or leukocytosis causing in-vitro potassium release
If suspected, repeat measurement with proper sampling technique or obtain arterial sample 1. Consider whether hemolysis occurred in the test tube versus in the body 1.
Clinical Pitfalls to Avoid
Assuming normal renal function: Even mild CKD (eGFR 45-60) significantly increases hyperkalemia risk, particularly with concurrent illness or dehydration 3
Overlooking dietary/herbal causes: Many patients don't consider herbal supplements as "medications" and won't report them unless specifically asked 1
Missing acute triggers: Fever, diarrhea, or dehydration can precipitate severe hyperkalemia in patients with borderline renal function 6
Ignoring the 2-4% baseline prevalence: Hyperkalemia occurs in 2-4% of the general population without obvious risk factors 1
Mortality and Morbidity Impact
Hyperkalemia significantly increases mortality risk—every 0.1 mEq/L rise in serum potassium ≥5.0 mEq/L increases all-cause mortality 7. Severe hyperkalemia (≥6.5 mEq/L) requiring hospitalization carries up to 31% inpatient mortality 7. The risk extends beyond cardiac arrhythmias to include peripheral neuropathy and renal tubular acidosis 4.
Life-threatening cardiac complications can occur at variable thresholds—some patients tolerate levels up to 6 mEq/L without arrhythmias, especially those with chronic conditions, while others develop fatal arrhythmias at lower levels 1. ECG changes (peaked T waves, widened QRS, absent P waves) indicate urgent cardiotoxicity requiring immediate treatment 2.